• SKIP TO CONTENT
  • SKIP NAVIGATION
  • Patient Resources
    • Clinical Trial Listings
    • What are Clinical Trials?
    • Become a Clinical Trial Volunteer
    • Useful Resources
    • FDA Approved Drugs
  • Professional Resources
    • Research Center Profiles
    • Market Research
    • Benchmark Reports
    • FDA Approved Drugs
    • Training Guides
    • Books
    • eLearning
    • Events
    • Newsletters
    • White Papers
    • SOPs
  • White Papers
  • Clinical Trial Listings
  • Advertise
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » Directories » FDA Approved Drugs » Tracleer (bosentan)

AND
  • A
  • B
  • C
  • D
  • E
  • F
  • G
  • H
  • I
  • J
  • K
  • L
  • M
  • N
  • O
  • P
  • Q
  • R
  • S
  • T
  • U
  • V
  • W
  • X
  • Y
  • Z

Tracleer (bosentan)

  • Profile

Profile

Contact Information

Currently Enrolling Trials

    Show More

    General Information

    Tracleer tablets have been approved by the FDA for the treatment of pulmonary arterial hypertension (PAH). This drug is indicated for use in improving exercise ability and decreasing the rate of clinical worsening in patients with WHO Class III or IV symptoms. Tracleer 125 mg (taken twice a day) is the first approved oral treatment for patients with PAH.

    Tracleer belongs to a class of drugs known as endothelin receptor antagonists (ERAs). Patients with PAH have elevated levels of endothelin, a potent blood vessel constrictor, in their plasma and lung tissue. Tracleer blocks the binding of endothelin to its receptors, thereby negating endothelin's deleterious effects.

    Clinical Results

    Results of a pivotal trial known as BREATHE-1 (Bosentan: Randomized Trial of Endothelin Receptor Antagonist THErapy) supported the approval of Tracleer. In the 213-subject trial, Tracleer (125 mg b.i.d. and 250 mg b.i.d.) was administered on a twice-daily basis. For both primary and secondary PAH, results showed statistically significant improvements versus placebo in the primary efficacy endpoint, exercise capacity. The overall treatment effect for both doses of Tracleer combined was a 44-meter improvement in walking distance compared to placebo (as measured by a six-minute walk test). Tracleer also produced a significant delay in time to clinical worsening, defined as death, hospitalization, worsening PAH or initiation of intravenous therapy. Lastly, treatment with Tracleer resulted in significant improvement in functional status and breathlessness.

    Side Effects

    Adverse reactions reported in clinical testing of Tracleer include (but are not limited to) the following:

    • Headache
    • Nasopharyngitis (inflammation of the nose and pharynx)
    • Flushing
    • Edema, lower limb
    • Hypotension
    • Palpitations

    Women who are pregnant, or who may become pregnant, should not take Tracleer due to the risk of birth defects. Additionally, patients receiving Tracleer should undergo monthly liver monitoring to ensure that proper enzyme levels are maintained.

    Mechanism of Action

    Endothelin-1 (ET-1) is a neurohormone, the effects of which are mediated by binding to ETA and ETB receptors in the endothelium and vascular smooth muscle. ET-1 concentrations are elevated in plasma and lung tissue of patients with pulmonary arterial hypertension, suggesting a pathogenic role for ET-1 in this disease. Bosentan is a specific and competitive antagonist at endothelin receptor types ETA and ETB . Bosentan has a slightly higher affinity for ETA receptors than for ETB receptors (from Tracleer Prescribing Information).

    Additional Information

    For additional information on Tracleer, please visit www.tracleer.com.

    Approval Date: 2001-11-01
    Company Name: Actelion
    Back to Listings

    Upcoming Events

    • 05Dec

      Thriving in Clinical Research – Overcoming Common Challenges as a Site: Part 3 – Site Resourcing

    • 14Apr

      MAGI 2024: The Clinical Research Conference

    Featured Products

    • Surviving an FDA GCP Inspection

      Surviving an FDA GCP Inspection: Resources for Investigators, Sponsors, CROs and IRBs

    • Best Practices for Clinical Trial Site Management

      Best Practices for Clinical Trial Site Management

    Featured Stories

    • Jonathan Seltzer

      Thought Leadership: Remote Patient Monitoring Gives New View of Safety in Cardiac Clinical Trials

    • Quality_Compass-360x240.png

      Ask the Experts: Applying Quality by Design to Protocols

    • Obesity Treatment Patient

      Clinical Trials Need Greater Representation of Obese Patients, Experts Say

    • Modernize-360x240.png

      FDA IT Modernization Plan Prioritizes Data-Sharing, AI, Collaboration and More

    Standard Operating Procedures for Risk-Based Monitoring of Clinical Trials

    The information you need to adapt your monitoring plan to changing times.

    Learn More Here
    • About Us
    • Contact Us
    • Privacy Policy
    • Do Not Sell or Share My Data

    Footer Logo

    300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

    Phone 703.538.7600 – Toll free 888.838.5578

    Copyright © 2023. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing